In Brief: FDA Panel Rejects Novartis’ Panobinostat, Gilead Files Stribild Successor
Executive Summary
Also, agency tells AEterna Zentaris its growth hormone deficiency drug Macrilen requires a new confirmatory trial, and privately held Spriaso announces FDA acceptance of NDA for Rinotuss12, a solid oral dose cough/cold product combining codeine and chlorpheniramine.